Information Provided By: 
Fly News Breaks for January 20, 2017
ENDP
Jan 20, 2017 | 05:56 EDT
JPMorgan analyst Chris Schott downgraded Endo International to Neutral saying the generic operating environment remains challenging. The analyst does not see fundamentals bottoming until the second half of 2017 at the earliest. Schott highlights the "bearish" generic pricing commentary at his firm's recent healthcare conference as well as Teva's disappointing guidance update. He lowered his price target for Endo shares to $20 from $30.
News For ENDP From the Last 2 Days
There are no results for your query ENDP
